<DOC>
	<DOCNO>NCT00842829</DOCNO>
	<brief_summary>Breakthrough cancer pain ( BTcP ) common problem patient cancer . Fentanyl Buccal Tablet ( FBT ) use treatment BTP adult cancer already receive maintenance opioid therapy chronic cancer pain . FBT treatment individually titrate effective dose provide adequate analgesia minimize undesirable effect . To reach safe effective dose individual patient soon possible , dose titration process critical . The aim study , conduct pragmatic condition large-scale population cancer patient compare proportion patient reach effective FBT dose titration start either 100 mcg dose 200 mcg dose .</brief_summary>
	<brief_title>Study Breakthrough Cancer Pain : Assessment Fentanyl Buccal Tablets Titration Treatment Opioid-Tolerant Patients</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>The patient willing provide write informed consent participate study . The patient either outpatient inpatient . The patient histologically documented diagnosis cancer . The patient stable background pain due cancer . The patient experience 4 BTcP episode per 24 hour . As maintenance opioid therapy , patient currently take 1 follow : least 60 mg oral morphine/day , least 25 mcg transdermal fentanyl/hour , least 30 mg oxycodone/day , least 8 mg hydromorphone/day , equianalgesic dose another opioid week long administration first dose study drug . Women childbearing potential , use medically accept , highly effective method birth control agree continue use method duration study . The patient must willing able successfully selfadminister study drug fill study document . The patient without maintenance opioid therapy . The patient uncontrolled rapidly escalate pain determine investigator . The patient know suspected hypersensitivity , allergy , contraindication active drug excipients study drug . The patient respiratory depression chronic obstructive pulmonary disease , medical condition predispose respiratory depression . The patient medical psychiatric disease , opinion investigator , would compromise collect data . The patient expect surgery study . The patient pregnant lactating . The patient participate study involve investigational drug prior 30 day . The patient receive monoamine oxidase inhibitor ( MAOI ) within 14 day first treatment study drug . The patient medical condition receive concomitant medication/therapy ( e.g. , regional nerve block ) could , opinion investigator , compromise patient 's safety compliance study protocol , compromise collect data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Breakthrough Cancer Pain</keyword>
</DOC>